bluebird bio Q4 Sales $7.80M May Not Be Comparable To $16.68M Estimate
Portfolio Pulse from Benzinga Newsdesk
bluebird bio (NASDAQ:BLUE) reported Q4 sales of $7.80 million, missing the consensus estimate of $16.68 million by 53.24%. However, this represents a 7.70K% increase from the same period last year, where sales were $100.00 thousand.
March 26, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
bluebird bio reported Q4 sales of $7.80 million, significantly missing the consensus estimate of $16.68 million, but showed a substantial year-over-year growth.
The significant miss in sales estimates for Q4 is likely to negatively impact investor sentiment and the stock price of bluebird bio in the short term. However, the remarkable year-over-year growth indicates strong sales momentum, which might mitigate some negative effects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100